A foundation model with weak experiential guidance in detecting muscle invasive bladder cancer on MRI.

Cancer Lett

Department of Radiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, P.R. China, 210029; The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu Province, China. Electronic address:

Published: January 2025

Preoperative detection of muscle-invasive bladder cancer (MIBC) remains a great challenge in practice. We aimed to develop and validate a deep Vesical Imaging Network (ViNet) model for the detection of MIBC using high-resolution Tweighted MR imaging (hrTWI) in a multicenter cohort. ViNet was designed using a modified 3D ResNet, in which, the encoder layers were pretrained using a self-supervised foundation model on over 40,000 cross-modal imaging datasets for transfer learning, and the classification modules were weakly supervised by an experiential knowledge-domain mask indicated by a nnUNet segmentation model. Optimal ViNet model was trained in derivation data (cohort 1, n = 312) and validated in multicenter data (cohort 2, n = 79; cohort 3, n = 44; cohort 4, n = 56) across a multi-ablation-test for model selection. In internal validation, ViNet using hrTWI outperformed all ablation-test models (odds ratio [OR], 7.41 versus 1.85 - 2.70; all P < 0.05). In external validation, the performance of ViNet using hrTWI versus ablation-test models was heterogeneous (OR, 1.31 - 3.89 versus 0.89 - 9.75; P = 0.03 - 0.15). In addition, clinical benefit of ViNet was evaluated between six readers using the Vesical Imaging-Reporting and Data System (VI-RADS) versus ViNet-adjusted VI-RADS. As a result, ViNet-adjusted VI-RADS upgraded 62.9% (17/27) of MIBC missed in VI-RADS score 2, while downgraded 84.1% (69/84), 62.5% (35/56) and 67.9% (19/28) of non-muscle-invasive bladder cancer (NMIBC) overestimated in VI-RADS score 3-5. We concluded that ViNet presents a promising alternative for diagnosing MIBC using hrT2WI instead of conventional multiparametric MRI.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2025.217438DOI Listing

Publication Analysis

Top Keywords

bladder cancer
12
foundation model
8
vinet model
8
data cohort
8
cohort cohort
8
vinet hrtwi
8
ablation-test models
8
vinet-adjusted vi-rads
8
vi-rads score
8
vinet
7

Similar Publications

[Detection and interpretation of PD-L1 in urologic neoplasms].

Zhonghua Bing Li Xue Za Zhi

January 2025

Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing100191, China.

Immune checkpoint inhibitors targeting PD-1/PD-L1 are gradually being applied in the treatment of advanced urinary system tumors. Immunohistochemical analysis of PD-L1 expression is the most popular method for screening suitable patients for immunotherapy and predicting therapeutic efficacy. The current application status of PD-L1 detection for urinary system tumors (mainly urothelial carcinoma), methods of the different antibody tests and the precautions, challenges and solutions in the interpretation of immunostaining were summarized in this review.

View Article and Find Full Text PDF

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.

J Immunother Cancer

January 2025

NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

Background: The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). However, the clinical significance and impact on tumor immune contexture of amplification in UC remain unclear.

Methods: This study analyzed 240 patients with UC with matched clinical annotations from two local cohorts (ZSHS cohort and FUSCC cohort).

View Article and Find Full Text PDF

Background And Purpose: Late toxicity is substantial after chemotherapy for anal cancer. This study aimed to investigate the relationship between radiation dose to lower urinary tract sub-structures and the risk of late urinary toxicities, in patients with anal cancer treated with chemoradiotherapy or radiotherapy.

Materials And Methods: From 2015 to 2021, 314 patients with localized anal cancer were included in a national prospective registration study.

View Article and Find Full Text PDF

Bladder cancer (BCa) is a common and lethal disease characterized by high recurrence rates and limited treatment options. Understanding the molecular pathways of BCa progress is crucial for investigating more effective targeted therapies. While ADAMTS12 is known to contribute to cancer progression and treatment resistance, its prognostic significance and underlying mechanisms in BCa remain poorly understood.

View Article and Find Full Text PDF

Exploration of an adaptive proton therapy strategy using CBCT with the concept of digital twins.

Phys Med Biol

January 2025

Department of Radiology Oncology, Emory University, Clifton Rd, Atlanta, Georgia, 30322-1007, UNITED STATES.

This study aims to develop a digital twin (DT) framework to achieve adaptive proton prostate stereotactic body radiation therapy (SBRT) with fast treatment plan selection and patient-specific clinical target volume (CTV) setup uncertainty. Prostate SBRT has emerged as a leading option for external beam radiotherapy due to its effectiveness and reduced treatment duration. However, interfractional anatomy variations can impact treatment outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!